Antibiotic treatment for nontuberculous mycobacterial lung disease

Expert Review of Respiratory Medicine

Volumn 10, Issue 5, 2016, Pages 557-568

  Kang, Young Ae ^a   Koh, Won Jung ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

lung disease; Mycobacterium abscessus; Mycobacterium avium complex; Mycobacterium kansasii; Nontuberculous mycobacteria

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; CLINICAL TRIAL (TOPIC); DRUG MONITORING; DRUG SCREENING; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; IMMUNOCOMPETENCE; INCIDENCE; LUNG INFECTION; MIXED INFECTION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM KANSASII; NONHUMAN; PRACTICE GUIDELINE; RECURRENT DISEASE; REVIEW; LUNG; LUNG DISEASES; MICROBIOLOGY; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; HUMANS; LUNG; LUNG DISEASES; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; TREATMENT OUTCOME;

EID: 84962050744     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2016.1165611     Document Type: Review

References (99)

1. Tortoli E. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clin Microbiol Rev. 2014; 27 (4): 727-52.
2. van Ingen J. Microbiological diagnosis of nontuberculous mycobacterial pulmonary disease. Clin Chest Med. 2015; 36 (1): 43-54.
3. Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med. 2013; 34 (1): 87-94.
4. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015; 36 (1): 13-34.
5. Adjemian J, Olivier KN, Seitz AE, et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012; 185 (8): 881-886.
6. Marras TK, Mendelson D, Marchand-Austin A, et al. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis. 2013; 19 (11): 1889-1891.
7. Moore JE, Kruijshaar ME, Ormerod LP, et al. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health. 2010; 10: 612.
8. Ide S, Nakamura S, Yamamoto Y, et al. Epidemiology and clinical features of pulmonary nontuberculous mycobacteriosis in Nagasaki, Japan. PLoS One. 2015; 10 (5): e0128304.
9. Koh WJ, Chang B, Jeong BH, et al. Increasing recovery of nontuberculous mycobacteria from respiratory specimens over a 10-year period in a tertiary referral hospital in South Korea. Tuberc Respir Dis (Seoul). 2013; 75 (5): 199-204.
10. Chien JY, Lai CC, Sheng WH, et al. Pulmonary infection and colonization with nontuberculous mycobacteria, Taiwan, 2000-2012. Emerg Infect Dis. 2014; 20 (8): 1382-1385.
11. Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013; 42 (6): 1604-1613.
12. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175 (4): 367-416
13. Thomson RM, Yew WW. When and how to treat pulmonary non-tuberculous mycobacterial diseases. Respirology. 2009; 14 (1): 12-26.
14. Marras TK, Prevots DR, Jamieson FB, et al. Opinions differ by expertise in Mycobacterium avium complex disease. Ann Am Thorac Soc. 2014; 11 (1): 17-22.
15. Marras TK, Prevots DR, Jamieson FB, et al. Variable agreement among experts regarding Mycobacterium avium complex lung disease. Respirology. 2015; 20 (2): 348-351.
16. Adjemian J, Prevots DR, Gallagher J, et al. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014; 11 (1): 9-16.
17. Boyle DP, Zembower TR, Reddy S, et al. Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species. Am J Respir Crit Care Med. 2015; 191 (11): 1310-1317.
18. Kwon YS, Koh WJ. Diagnosis of pulmonary tuberculosis and nontuberculous mycobacterial lung disease in Korea. Tuberc Respir Dis (Seoul). 2014; 77 (1): 1-5.
19. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest. 2004; 126 (2): 566-581.
20. British Thoracic Society. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Int J Tuberc Lung Dis. 2002; 6 (7): 628-634.
21. Griffith DE, Brown-Elliott BA, Shepherd S, et al. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2005; 172 (2): 250-253.
22. Griffith DE, Brown BA, Murphy DT, et al. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis. 1998; 178 (1): 121-126.
23. Griffith DE, Brown BA, Cegielski P, et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis. 2000; 30 (2): 288-292.
24. Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006; 173 (11): 1283-1289.
25. Wallace RJ Jr., Brown-Elliott BA, McNulty S, et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest. 2014; 146 (2): 276-8.
26. Jeong BH, Jeon K, Park HY, et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015; 191 (1): 96-103.
27. Philley JV, Griffith DE. Treatment of slowly growing mycobacteria. Clin Chest Med. 2015; 36 (1): 79-90.
28. Wallace RJ Jr., Brown BA, Griffith DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med. 1994; 149 (5): 1335-1341.
29. Wallace RJ Jr., Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996; 153 (6 Pt 1): 1766-1772.
30. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999; 160 (3): 866-872.
31. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007; 101 (1): 130-138.
32. Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis. 1999; 28 (5): 1080-1085.
33. Miwa S, Shirai M, Toyoshima M, et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A Preliminary Study. Ann Am Thorac Soc. 2014; 11 (1): 23-29.
34. van Ingen J, Boeree MJ, van Soolingen D, et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat. 2012; 15 (3): 149-6.
35. van Ingen J, Ferro BE, Hoefsloot W, et al. Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence. Expert Rev Anti Infect Ther. 2013; 11 (10): 1065-1077.
36. van Ingen J, Kuijper EJ. Drug susceptibility testing of nontuberculous mycobacteria. Future Microbiol. 2014; 9 (9): 1095-1110.
37. Kobashi Y, Abe M, Mouri K, et al. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother. 2012; 18 (4): 436-443.
38. Brown-Elliott BA, Iakhiaeva E, Griffith DE, et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol. 2013; 51 (10): 3389-3394.
39. Wallace RJ Jr., Brown BA, Griffith DE, et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis. 1995; 171 (3): 747-750.
40. van Ingen J, Egelund EF, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012; 186 (6): 559-65.
41. Koh WJ, Jeong BH, Jeon K, et al. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012; 186 (8): 797-802.
42. Xu HB, Jiang RH, Li L. Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2014; 33 (3): 347-358.
43. Lee BY, Kim S, Hong Y, et al. Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2015; 59 (6): 2972-2977.
44. Min J, Park J, Lee YJ, et al. Determinants of recurrence after successful treatment of Mycobacterium avium complex lung disease. Int J Tuberc Lung Dis. 2015; 19 (10): 1239-1245.
45. Jarand J, Davis JP, Cowie RL, et al. Long term follow up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or fifampin. Chest. 2015 Oct 29. doi: 10.1378/chest.15-0543. [Epub ahead of print].
46. Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis. 2012; 25 (2): 218-227.
47. Koh WJ, Jeong BH, Jeon K, et al. Response to switch from intermittent therapy to daily therapy for refractory nodular bronchiectatic Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2015; 59 (8): 4994-4996.
48. Koh WJ, Hong G, Kim SY, et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013; 57 (5): 2281-2285.
49. Jo KW, Kim S, Lee JY, et al. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy. J Infect Chemother. 2014; 20 (10): 602-606.
50. Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006; 174 (8): 928-934.
51. Kohno Y, Ohno H, Miyazaki Y, et al. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob Agents Chemother. 2007; 51 (11): 4071-4076.
52. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest. 2003; 124 (4): 1482-1486.
53. van Ingen J, Totten SE, Helstrom NK, et al. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012; 56 (12): 6324-6327.
54. Ferro BE, Meletiadis J, Wattenberg M, et al. Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin. Antimicrob Agents Chemother. 2016; 60 (2): 1097-1105.
55. Davis KK, Kao PN, Jacobs SS, et al. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med. 2007; 7: 2.
56. Olivier KN, Shaw PA, Glaser TS, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc. 2014; 11 (1): 30-5.
57. Hagerman JK, Hancock KE, Klepser ME. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv. 2006; 3 (1): 71-86.
58. Griffith DE, Philley JV, Brown-Elliott BA, et al. The significance of Mycobacterium abscessus subspecies abscessus isolation during Mycobacterium avium complex lung disease therapy. Chest. 2015; 147 (5): 1369-1375.
59. Koh WJ, Stout JE, Yew WW. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex. Int J Tuberc Lung Dis. 2014; 18 (10): 1141-1148.
60. Howard ST. Recent progress towards understanding genetic variation in the Mycobacterium abscessus complex. Tuberculosis (Edinb). 2013; 93 (Suppl): S15-20.
61. Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Mycobacterium abscessus. "Pleased to meet you, hope you guess my name.". Ann Am Thorac Soc. 2015; 12 (3): 436-439
62. Lee MR, Sheng WH, Hung CC, et al. Mycobacterium abscessus complex infections in humans. Emerg Infect Dis. 2015; 21 (9): 1638-1646.
63. Clinical and Laboratory Standards Institute (CLSI). Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. 2nd ed. CLSI document No. M24-A2, Wayne, PA: Clinical Laboratory Standards Institute; 2011.
64. Kasperbauer SH, De Groote MA. The treatment of rapidly growing mycobacterial infections. Clin Chest Med. 2015; 36 (1): 67-78.
65. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm (41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009; 53 (4): 1367-1376.
66. Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm (41) and rrl sequencing. Antimicrob Agents Chemother. 2011; 55 (2): 775-781.
67. Lee SH, Yoo HK, Kim SH, et al. Detection and assessment of clarithromycin inducible resistant strains among Korean Mycobacterium abscessus clinical strains: PCR methods. J Clin Lab Anal. 2014; 28 (5): 409-414.
68. Brown-Elliott BA, Vasireddy S, Vasireddy R, et al. Utility of sequencing the erm (41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. J Clin Microbiol. 2015; 53 (4): 1211-1215.
69. Shallom SJ, Moura NS, Olivier KN, et al. New real-time PCR assays for detection of inducible and acquired clarithromycin resistance in the Mycobacterium abscessus group. J Clin Microbiol. 2015; 53 (11): 3430-3437.
70. Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012; 186 (9): 917-925.
71. Maurer FP, Castelberg C, Quiblier C, et al. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. J Antimicrob Chemother. 2014; 69 (6): 1559-1563.
72. Maurer FP, Ruegger V, Ritter C, et al. Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm (41). J Antimicrob Chemother. 2012; 67 (11): 2606-2611.
73. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis. 1993; 147 (5): 1271-1278.
74. Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009; 180 (9): 896-902.
75. Lyu J, Jang HJ, Song JW, et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med. 2011; 105 (5): 781-787.
76. Jarand J, Levin A, Zhang L, et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011; 52 (5): 565-571.
77. Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011; 183 (3): 405-10.
78. Lyu J, Kim BJ, Kim BJ, et al. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. Respir Med. 2014; 108 (11): 1706-1712.
79. Harada T, Akiyama Y, Kurashima A, et al. Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol. 2012; 50 (11): 3556-3561.
80. Roux AL, Catherinot E, Soismier N, et al. Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. J Cyst Fibros. 2015; 14 (1): 63-69.
81. Huang CW, Chen JH, Hu ST, et al. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. Int J Antimicrob Agents. 2013; 41 (3): 218-223.
82. Wallace RJ Jr., Dukart G, Brown-Elliott BA, et al. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother. 2014; 69 (7): 1945-53.
83. Shen GH, Wu BD, Hu ST, et al. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents. 2010; 35 (4): 400-404.
84. Nie W, Duan H, Huang H, et al. Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65, and susceptibility testing to eight antibiotics. Int J Infect Dis. 2014; 25: 170-174.
85. Kim SY, Kim CK, Bae IK, et al. The drug susceptibility profile and inducible resistance to macrolides of Mycobacterium abscessus and Mycobacterium massiliense in Korea. Diagn Microbiol Infect Dis. 2015; 81 (2): 107-111.
86. Tang SS, Lye DC, Jureen R, et al. Rapidly growing mycobacteria in Singapore, 2006-2011. Clin Microbiol Infect. 2015; 21 (3): 236-241.
87. Czaja CA, Levin AR, Cox CW, et al. Improvement in quality of life after therapy for Mycobacterium abscessus group lung infection. A Prospective Cohort Study. Ann Am Thorac Soc. 2016; 13 (1): 40-48.
88. Winthrop KL, Ku JH, Marras TK, et al. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J. 2015; 45 (4): 1177-1179.
89. Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016; 71 (Suppl 1): i1-i22.
90. Philley JV, Wallace RJ Jr., Benwill JL, et al. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest. 2015; 148 (2): 499-506.
91. Ahn CH, Lowell JR, Ahn SS, et al. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis. 1983; 128 (6): 1048-1050.
92. BTS. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. Thorax. 1994; 49 (5): 442-445.
93. Shitrit D, Baum GL, Priess R, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest. 2006; 129 (3): 771-776.
94. Moon SM, Park HY, Jeon K, et al. Clinical significance of Mycobacterium kansasii isolates from respiratory specimens. PLoS One. 2015; 10 (10): e0139621.
95. Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis. 2003; 37 (9): 1178-1182.
96. Ahn CH, Wallace RJ Jr., Steele LC, et al. Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii. Am Rev Respir Dis. 1987; 135 (1): 10-16.
97. Wallace RJ Jr., Dunbar D, Brown BA, et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis. 1994; 18 (5): 736-743.
98. Griffith DE, Adjemian J, Brown-Elliott BA, et al. Semiquantitative culture analysis during therapy for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015; 192 (6): 754-760.
99. Falkinham JO 3rd. Reducing human exposure to Mycobacterium avium. Ann Am Thorac Soc. 2013; 10 (4): 378-382.